Spyre Therapeutics (SYRE) Accounts Payables (2015 - 2026)

Spyre Therapeutics has reported Accounts Payables for 12 years, with the latest figure at $50000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 98.64% year-over-year to $50000.0; the trailing twelve-month figure through Mar 2026 stood at $50000.0 (down 98.64% YoY), and the FY2025 full-year result was $14000.0, down 97.68% from the prior year.
• Accounts Payables for Q1 2026 stood at $50000.0, up from $14000.0 in the prior quarter.
• The five-year high for Accounts Payables was $20.8 million in Q2 2023, with the low at $14000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $4.3 million across 5 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables surged 962.82% — and 2025, when it sank 99.04%.
• Spyre Therapeutics' Accounts Payables stood at $677000.0 in 2022, then surged by 32.35% to $896000.0 in 2023, then sank by 32.7% to $603000.0 in 2024, then plunged by 97.68% to $14000.0 in 2025, then soared by 257.14% to $50000.0 in 2026.
• The last three Accounts Payables figures came in at $50000.0 (Q1 2026), $14000.0 (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.